<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290951</url>
  </required_header>
  <id_info>
    <org_study_id>R1979-HM-1333</org_study_id>
    <nct_id>NCT02290951</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies</brief_title>
  <official_title>An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV
      (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of
      REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2015</start_date>
  <completion_date type="Anticipated">June 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/overall frequency of adverse events</measure>
    <time_frame>Up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Concentration of REGN1979)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Peak plasma concentration (Cmax) of REGN1979</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (Anti-REGN1979 antibodies)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Anti-REGN1979 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) for patients with CLL</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental cohorts N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts N (participants with CD20+NHL) will receive multiple dose levels of REGN1979</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental cohorts C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental cohorts C (participants with CLL) will receive multiple dose levels of REGN1979</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1979 multiple dose levels</intervention_name>
    <arm_group_label>Experimental cohorts N</arm_group_label>
    <arm_group_label>Experimental cohorts C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Have documented CD20+ B-cell malignancy, with active disease not responsive to prior
             therapy, for whom no standard of care options exists, and for whom treatment with an
             anti-CD20 antibody may be appropriate:

          2. NHL patients must have had prior treatment with an anti-CD20 antibody therapy

          3. Must have at least one bi-dimensionally measurable lesion ≥1.5 cm) documented by CT
             scan.

          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          5. Life expectancy of at least 6 months

          6. Adequate bone marrow function documented by:

               1. Platelet counts ≥75 x 10^9/L

               2. Hb level ≥9 g/dL

               3. Absolute neutrophil count (ANC) ≥1 x 10^9/L

          7. Adequate organ function

          8. Willing and able to comply with clinic visits and study-related procedures

          9. Provide signed informed consent

        Key Exclusion Criteria:

          1. Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by
             non-primary CNS NHL

          2. History of or current relevant CNS pathology

          3. Allogeneic stem cell transplantation

          4. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis
             B virus (HBV) or hepatitis C virus (HCV).

          5. Known hypersensitivity to both allopurinol and rasburicase

          6. History of hypersensitivity to any compound in the tetracycline antibiotics group

        The information provided above is not intended to contain all considerations relevant to
        potential participation in a clinical trial therefore not all inclusion/ exclusion criteria
        are listed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

